# Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

> **NCT05688579** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Nanfang Li** · enrollment: 8000 (estimated)

## Conditions studied

- Hypertension
- Hyperaldosteronaemia

## Interventions

- **DRUG:** Mineralocorticoid Receptor Antagonists(MRAs)
- **OTHER:** Blank control

## Key facts

- **NCT ID:** NCT05688579
- **Lead sponsor:** Nanfang Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-04-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 8000 (ESTIMATED)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05688579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05688579, "Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05688579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*